Redeye updates its estimates and fair value range following Arise’s capital markets day and the new ...
Atria raised its guidance on 11 September and now expects adjusted EBIT to improve in 2023.
Redeye argues that the recent news regarding Integrum’s review and evaluation of strategic alternati...
PolarCool genomför nu en företrädesemission med teckningsperiod 18 september – 2 oktober år 2023.
This morning, Vow announced that the company has been awarded three contracts in its Industrial segm...
Redeye is optimistic about Cantargia’s new clinical trial of nadunolimab in acute myeloid leukaemia ...
Ascelias priority is to secure a re-reader evaluation of SPARKLE by May 2024.
Redeye updates our outlook after the SEK 440m (gross) directed rights issue priced at SEK 275, will ...
Redeye updates its estimates on the back of TECO’s Q2 report which showed progress on the project pi...
EasyFill AB (publ) meddelade den 14 september att bolaget har tecknat ett partneravtal med Lane Indu...
Väldiversifierad investeringsportfölj med låg operationell risk Stockwik har genom 24 omsorgsfullt u...
We terminate commissioned coverage on Raketech Group Holding.
Redeye comments on Energy Save’s (ES) Q1’23/24 report, showing weaker sales and profitability than e...
Redeye comments on EG7’s announcement that it is investing in a new IP where it acquires worldwide p...
Redeye strengthens its positive view of Transtema following the Swedish 5G deal with Telenor.
PolarCool meddelade igår den 13 september att bolaget nyligen har tecknat ett avtal med Portugals ru...
Today, Qlife disclosed its first collaboration since its new strategy of going to market with partne...
Sommarens aviserade finansieringslösning ger Hexicon möjlighet att fortsätta verksamhetsutvecklingen...
Intäkterna växte kraftigt under kvartalet och intressanta avtal väntas framgent.
The SEK 440m (gross) directed rights issue priced at SEK 275, will allow XVIVO to push the Liver Ass...
